• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

后性交生物利用度和 0.5% PRO 2000 凝胶的抗病毒活性:对未来杀微生物剂临床试验的影响。

Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.

机构信息

Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.

出版信息

PLoS One. 2010 Jan 22;5(1):e8781. doi: 10.1371/journal.pone.0008781.

DOI:10.1371/journal.pone.0008781
PMID:20107502
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2809740/
Abstract

BACKGROUND

The pharmacokinetics and pharmacodynamics of vaginal microbicides are typically assessed among sexually abstinent women. However, the physical act of sex may modulate gel distribution, and preclinical studies demonstrate seminal plasma interferes with the antiviral activity of several microbicides. This study compared the biological activity and concentration of PRO 2000 in cervicovaginal lavage (CVL) collected in the absence or following coitus.

METHODS

CVL samples were collected from ten heterosexual couples at baseline, after sex, after a single dose of 0.5% PRO 2000 gel and sex, and after gel application without sex. The impact of CVL on HIV-1 infection of TZM-bl cells and HSV-2 infection of CaSki cells was monitored by luciferase and plaque assay, respectively. PRO 2000 concentrations were measured by fluorescence.

RESULTS

CVL collected after PRO 2000 application significantly inhibited HIV-1 and HSV-2 (p = 0.01). However, the antiviral activity was reduced following sex and no significant protective effect was observed in postcoital CVL obtained in the presence compared to the absence of PRO 2000 for HIV (p = 0.45) or HSV-2 (p = 0.56). Less PRO 2000 was recovered in postcoital CVL, which, in conjunction with interference by seminal plasma, may have contributed to lower antiviral activity.

CONCLUSIONS

Postcoital responses to PRO 2000 differ from precoital measures and the results obtained may provide insights into the clinical trial findings in which there was no significant protection against HIV-1 or HSV-2. Postcoital studies should be incorporated into clinical studies before embarking on large-scale efficacy trials.

摘要

背景

阴道杀微生物剂的药代动力学和药效学通常在禁欲的女性中进行评估。然而,性行为的物理行为可能会调节凝胶的分布,并且临床前研究表明,精液会干扰几种杀微生物剂的抗病毒活性。本研究比较了 PRO 2000 在无性交和性交后收集的宫颈阴道灌洗液(CVL)中的生物学活性和浓度。

方法

在基线、性行为后、单次给予 0.5%PRO 2000 凝胶后和性行为后以及无性行为时应用凝胶后,从十对异性恋夫妇中收集 CVL 样本。通过荧光测定分别监测 CVL 对 TZM-bl 细胞中 HIV-1 感染和 CaSki 细胞中 HSV-2 感染的影响。通过荧光测定测量 PRO 2000 的浓度。

结果

在给予 PRO 2000 后收集的 CVL 显著抑制了 HIV-1 和 HSV-2(p = 0.01)。然而,性行为后抗病毒活性降低,并且在存在或不存在 PRO 2000 的情况下,性交后 CVL 中未观察到针对 HIV(p = 0.45)或 HSV-2(p = 0.56)的显著保护作用。在性交后 CVL 中回收的 PRO 2000 较少,这与精液的干扰一起,可能导致抗病毒活性降低。

结论

与性交前措施相比,性交后对 PRO 2000 的反应不同,并且获得的结果可能为临床试验结果提供深入了解,在这些试验中,对 HIV-1 或 HSV-2 没有明显的保护作用。在开始大规模疗效试验之前,应该将性交后研究纳入临床研究中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38a8/2809740/9919492d71ab/pone.0008781.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38a8/2809740/f9a0dd077142/pone.0008781.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38a8/2809740/b59b549ba31b/pone.0008781.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38a8/2809740/aff0fa0f6eda/pone.0008781.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38a8/2809740/0d16ea2fbe49/pone.0008781.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38a8/2809740/9919492d71ab/pone.0008781.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38a8/2809740/f9a0dd077142/pone.0008781.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38a8/2809740/b59b549ba31b/pone.0008781.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38a8/2809740/aff0fa0f6eda/pone.0008781.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38a8/2809740/0d16ea2fbe49/pone.0008781.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38a8/2809740/9919492d71ab/pone.0008781.g005.jpg

相似文献

1
Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.后性交生物利用度和 0.5% PRO 2000 凝胶的抗病毒活性:对未来杀微生物剂临床试验的影响。
PLoS One. 2010 Jan 22;5(1):e8781. doi: 10.1371/journal.pone.0008781.
2
PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.PRO 2000凝胶经阴道应用后可抑制HIV和单纯疱疹病毒感染:一项双盲安慰剂对照试验。
J Infect Dis. 2006 Jan 1;193(1):27-35. doi: 10.1086/498533. Epub 2005 Nov 17.
3
UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application.UC781 杀微生物剂凝胶在每日两次阴道应用后采集的宫颈阴道灌洗液中保持抗 HIV 活性。
Antimicrob Agents Chemother. 2012 Jul;56(7):3592-6. doi: 10.1128/AAC.00452-12. Epub 2012 Apr 16.
4
SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.SPL7013 凝胶(VivaGel®)在人体阴道给药后保持对 HIV-1 和 HSV-2 的强大抑制活性。
PLoS One. 2011;6(9):e24095. doi: 10.1371/journal.pone.0024095. Epub 2011 Sep 15.
5
First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics.卡拉胶凝胶共配制的MIV-150与醋酸锌的首次人体试验:安全性、药代动力学、可接受性、依从性和药效学。
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):489-496. doi: 10.1097/QAI.0000000000001136.
6
Herbal Gel Formulation Developed for Anti-Human Immunodeficiency Virus (HIV)-1 Activity Also Inhibits In Vitro HSV-2 Infection.一种用于抗人类免疫缺陷病毒 (HIV)-1 活性的草药凝胶制剂也可抑制体外单纯疱疹病毒 2 型感染。
Viruses. 2018 Oct 24;10(11):580. doi: 10.3390/v10110580.
7
The effect of menopause on the innate antiviral activity of cervicovaginal lavage.绝经对宫颈阴道灌洗的先天性抗病毒活性的影响。
Am J Obstet Gynecol. 2015 Aug;213(2):204.e1-6. doi: 10.1016/j.ajog.2015.03.045. Epub 2015 Mar 25.
8
Clinical development of microbicides for the prevention of HIV infection.用于预防艾滋病毒感染的杀微生物剂的临床开发。
Curr Pharm Des. 2004;10(3):315-36. doi: 10.2174/1381612043386374.
9
In Vitro Exposure to PC-1005 and Cervicovaginal Lavage Fluid from Women Vaginally Administered PC-1005 Inhibits HIV-1 and HSV-2 Infection in Human Cervical Mucosa.体外暴露于PC - 1005以及来自经阴道给予PC - 1005的女性的宫颈阴道灌洗液可抑制人宫颈黏膜中的HIV - 1和HSV - 2感染。
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5459-66. doi: 10.1128/AAC.00392-16. Print 2016 Sep.
10
Self-collected genital swabs compared with cervicovaginal lavage for measuring HIV-1 and HSV-2 and the effect of acyclovir on viral shedding.自我采集的生殖器拭子与宫颈阴道灌洗法在检测HIV-1和HSV-2方面的比较以及阿昔洛韦对病毒脱落的影响
Int J STD AIDS. 2017 Mar;28(4):372-379. doi: 10.1177/0956462416650123. Epub 2016 Jul 10.

引用本文的文献

1
Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention.促进女性参与科学和科学服务于女性:填补差距、应对挑战、把握机遇,以优化 HIV-1 预防的暴露前预防措施。
Front Immunol. 2022 Dec 6;13:1055042. doi: 10.3389/fimmu.2022.1055042. eCollection 2022.
2
Evaluating the impact of three progestin-based hormonal contraceptive methods on immunologic changes in the female genital tract and systemically (CHIME Study): a prospective cohort study protocol.评估三种基于孕激素的激素避孕方法对女性生殖道和全身免疫变化的影响(CHIME 研究):一项前瞻性队列研究方案。
BMC Womens Health. 2022 Nov 18;22(1):456. doi: 10.1186/s12905-022-02053-w.
3

本文引用的文献

1
Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception.女性生殖道分泌物抑制单纯疱疹病毒感染:与可溶性黏膜免疫介质的相关性及其对激素避孕的影响。
Am J Reprod Immunol. 2010 Feb;63(2):110-9. doi: 10.1111/j.1600-0897.2009.00768.x. Epub 2009 Dec 15.
2
The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1.候选磺化杀微生物剂PRO 2000对HIV-1可能具有多种作用机制。
Antiviral Res. 2009 Oct;84(1):38-47. doi: 10.1016/j.antiviral.2009.07.013. Epub 2009 Aug 5.
3
Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety.
Evaluation of the novel vaginal contraceptive agent PPCM in preclinical studies using sperm hyaluronan binding and acrosome status assays.
采用精子透明质酸结合和顶体状态检测方法评估新型阴道避孕剂 PPCM 在临床前研究中的效果。
Andrology. 2022 Feb;10(2):367-376. doi: 10.1111/andr.13110. Epub 2021 Oct 4.
4
Semen: A modulator of female genital tract inflammation and a vector for HIV-1 transmission.精液:女性生殖道炎症的调节剂和 HIV-1 传播的载体。
Am J Reprod Immunol. 2021 Nov;86(5):e13478. doi: 10.1111/aji.13478. Epub 2021 Jun 16.
5
Emergence of Nanotechnology to Fight HIV Sexual Transmission: The Trip of G2-S16 Polyanionic Carbosilane Dendrimer to Possible Pre-Clinical Trials.纳米技术在防治 HIV 性传播方面的应用:G2-S16 聚阴离子碳硅烷树枝状大分子向可能的临床前试验的迈进。
Int J Mol Sci. 2020 Dec 10;21(24):9403. doi: 10.3390/ijms21249403.
6
Heterogeneity of HIV-1 Replication in Ectocervical and Vaginal Tissue Ex Vivo.人乳头瘤病毒-1在离体子宫颈和阴道组织中复制的异质性
AIDS Res Hum Retroviruses. 2018 Feb;34(2):185-192. doi: 10.1089/AID.2017.0107. Epub 2017 Dec 14.
7
First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics.卡拉胶凝胶共配制的MIV-150与醋酸锌的首次人体试验:安全性、药代动力学、可接受性、依从性和药效学。
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):489-496. doi: 10.1097/QAI.0000000000001136.
8
Efficacy of HIV antiviral polyanionic carbosilane dendrimer G2-S16 in the presence of semen.HIV抗病毒聚阴离子碳硅烷树枝状大分子G2-S16在精液存在下的疗效。
Int J Nanomedicine. 2016 May 30;11:2443-50. doi: 10.2147/IJN.S104292. eCollection 2016.
9
Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.性别对1%替诺福韦凝胶药代动力学和药效学的影响。
Clin Infect Dis. 2016 Feb 1;62(3):375-382. doi: 10.1093/cid/civ913. Epub 2015 Oct 27.
10
Loss of Innate Host Defense Following Unprotected Vaginal Sex.无保护阴道性交后天然宿主防御功能丧失。
J Infect Dis. 2016 Mar 1;213(5):840-7. doi: 10.1093/infdis/jiv488. Epub 2015 Oct 13.
硫酸纤维素破坏紧密连接促进HIV感染:一种杀微生物剂安全性模型。
J Infect Dis. 2009 Aug 15;200(4):599-608. doi: 10.1086/600867.
4
Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission.硫酸纤维素凝胶预防阴道HIV传播无效。
N Engl J Med. 2008 Jul 31;359(5):463-72. doi: 10.1056/NEJMoa0707957.
5
Enhancement of HIV infection by cellulose sulfate.硫酸纤维素增强HIV感染
AIDS Res Hum Retroviruses. 2008 Jul;24(7):925-9. doi: 10.1089/aid.2008.0043.
6
Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model.候选杀微生物剂PPCM在细胞和组织培养中可阻断1型人类免疫缺陷病毒感染,并在小鼠模型中预防生殖器疱疹。
J Virol. 2008 Jul;82(13):6576-84. doi: 10.1128/JVI.00335-08. Epub 2008 Apr 23.
7
Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides.开发用于局部杀菌剂发现和临床前测试的综合1型人类免疫缺陷病毒筛查算法。
Antimicrob Agents Chemother. 2008 May;52(5):1768-81. doi: 10.1128/AAC.01328-07. Epub 2008 Mar 3.
8
SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria.用于预防艾滋病毒感染的精明阴道凝胶(C31G):在尼日利亚进行的一项随机对照试验
PLoS One. 2008 Jan 23;3(1):e1474. doi: 10.1371/journal.pone.0001474.
9
Semen-derived amyloid fibrils drastically enhance HIV infection.精液衍生的淀粉样纤维显著增强HIV感染。
Cell. 2007 Dec 14;131(6):1059-71. doi: 10.1016/j.cell.2007.10.014.
10
Seminal plasma reduces the effectiveness of topical polyanionic microbicides.精浆会降低局部使用的聚阴离子杀微生物剂的效果。
J Infect Dis. 2007 Nov 1;196(9):1394-402. doi: 10.1086/522606. Epub 2007 Sep 26.